Thrombosis and infections associated with PICC in onco‑hematological patients, what is their relevance?
-
Manuel Sánchez Cánovas [3] ; Esmeralda García Torralba [3] ; Noel Blaya Boluda [3] ; Ana Sánchez Saura [1] ; Gabriel Puche Palao [4] ; Ana Sánchez Fuentes [2] ; Lorena Martínez Montesinos [2] ; Carmen Poveda Ganga [2] ; Lucía García Tomas [2] ; Josefa Bayona Jiménez [5] ; Ángeles Cos Zapata [5] ; Carmen María Muñoz Jurado [5] ; Inmaculada Pina Mingorance [5] ; María Amor Caravaca Hernández [5] ; Vicente Vicente García [2] ; Francisco Ayala de la Peña [3]
-
[1] Hospital Virgen de la Arrixaca
Hospital Virgen de la Arrixaca
Murcia, España
-
[2] Universidad de Murcia
Universidad de Murcia
Murcia, España
-
[3] Medical Oncology Department, IMIB, Hospital Universitario Morales Meseguer, Universidad de Murcia, Murcia, Spain
-
[4] Internal Medicine Department, Hospital G. Universitario Reina Sofía, Murcia, Spain
-
[5] Onco—Hematological Day Hospital Unit, IMIB, Hospital Universitario Morales Meseguer, Universidad de Murcia, Murcia, Spain
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 12, 2024, págs. 3226-3235
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Purpose Peripherally inserted central venous catheters (PICC) in the onco-hematological patients may be associated with thrombosis or infections that may have short- to medium-term repercussions.
Material and methods Single-centre retrospective analysis of a prospectively collected cohort. Primary objective was to establish the PICC-thrombosis and infections incidence. Secondary objectives were to analyze profle of patients sufering from these complications and variables associated with an increased likelihood of developing these events.
Results 549 patients were recruited. 58.5% (n=321) were oncology patients and 41.5% (n=228) hematology patients. The incidence of PICC-associated thrombosis was 3.5% (n=19). Thrombosis was associated with progression of the underlying malignant pathology in 10.6% (n=2) of cases. No association was found between clinical variables analysed and development of thrombosis. Incidence of PICC-associated infections was 7.65% (n=42). In the 30 days prior to PICC infection, 57.1% (n=24) had a febrile syndrome of another focus, 73.8% (n=11) had been hospitalized, 49.5% (n=25) had a neutrophil count of 0–500 cells/mm3 and 47.6% (n=20) had an episode of neutropenic fever. Variables signifcantly associated with the development of infection were hematological patients, high-fow PICC, 3-lm PICC or PICC insertion because of administration of vesicant therapy.
Conclusions Incidence of PICC-associated thrombosis is low and apparently less prognostically aggressive than other forms of thrombosis associated with cancer, without identify predictive factors. Infection was more prevalent and the identifcation of risk factors in our series could facilitate its prevention.
